Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:23:13 EDT Sat 05 Jul 2025
Enter Symbol
or Name
USA
CA



Q:PRTC - PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PRTC - Q3.217.21·28.600.218.01+0.865.00.717.91  18.01  17.9124.99  13.30Jul 03Jun 2615 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-26 02:00U:PRTCNews ReleasePureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
2025-06-16 12:59U:PRTCNews ReleasePureTech Health: Results of Annual General Meeting
2025-05-22 07:00U:PRTCNews ReleasePureTech to Present at the Jefferies Global Healthcare Conference
2025-05-20 17:15U:PRTCNews ReleasePureTech's Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
2025-05-09 07:00U:PRTCNews ReleasePureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
2025-05-01 07:00U:PRTCNews ReleasePureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
2025-04-30 02:00U:PRTCNews ReleasePureTech Announces Annual Results for Year Ended December 31, 2024
2025-04-23 02:00U:PRTCNews ReleasePureTech Health: Notice of Results
2025-04-09 02:00U:PRTCNews ReleasePureTech Appoints Peel Hunt as Joint UK Corporate Broker
2025-04-07 12:16U:PRTCNews ReleasePureTech Health plc Statement Regarding Press Speculation
2025-03-11 07:05U:PRTCNews ReleasePureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
2025-02-25 07:27U:PRTCNews ReleasePureTech to Present at the Leerink Partners Global Healthcare Conference
2025-02-12 07:05U:PRTCNews ReleasePureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
2025-01-27 02:00U:PRTCNews ReleasePureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
2025-01-09 07:00U:PRTCNews ReleasePureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
2025-01-08 07:00U:PRTCNews ReleasePureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
2025-01-06 02:00U:PRTCNews ReleasePureTech Appoints UBS as UK Corporate Broker
2024-12-16 02:00U:PRTCNews ReleasePureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
2024-12-11 07:05U:PRTCNews ReleasePureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
2024-12-09 02:00U:PRTCNews ReleasePureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting